secwatch.observer — SEC 8-K summary
======================================

Issuer:     SANGAMO THERAPEUTICS, INC (SGMO)
CIK:        0001001233
Form:       8-K
Filed at:   2023-02-22T23:59:59+00:00
Accession:  0001628280-23-004552
Event type: earnings
Sentiment:  negative
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Sangamo reports Q4 net loss $52M, cash down to $307.5M; halts sickle cell investment, seeks partner
--------------------------------------------------------------------------------

- Q4 2022 net loss $52.0M ($0.32/share) vs $37.5M loss in Q4 2021.
- Full year 2022 net loss $192.3M ($1.25/share) vs $178.3M in 2021.
- Cash and marketable securities $307.5M at Dec 31, 2022, down from $464.7M a year ago.
- 2023 GAAP operating expense guidance $310-330M; non-GAAP $275-295M.
- Discontinuing material investments in sickle cell program; seeking collaboration partner for Phase 3.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1001233/000162828023004552/0001628280-23-004552-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1001233/000162828023004552/sgmo-20230222.htm
  HTML page:      https://secwatch.observer/filing/0001628280-23-004552

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer